Cellares and City of Hope announced a collaboration to evaluate automated manufacturing of City of Hope’s investigational gene-modified CAR T-cell therapy targeting glioblastoma multiforme, an aggressive solid tumor brain cancer with limited treatment options.
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe







